Citations

Showing 10 of 108094 citations.

The impact of violence on healthcare workers' mental health in conflict based settings amidst COVID‐19 pandemic, and potential interventions: A narrative review
Rija, Aiman , Islam, Zarmina , Bilal, Wajeeha , Qamar, Khulud , Gangat, Shazil Ahmed , Abbas, Samina , Mirha, Hania Tul , Mohanan, Parvathy , Shaeen, Sean Kaisser , Klouche-Djedid, Selma Nihel , Essar, Mohammad Yasir , Essar, Mohammad Yasir , Rahmat, Zainab Syyeda , Kashyap, Rahul

Mayo Clinic

Health Science Reports | November 7, 2022 | Volume: 5 | Issue: 6 | Pages: No page available

10.1002/hsr2.920 | PMID 36381415 Get It

AbstractHealthcare workers (HCWs) have faced an increased amount of mental health struggles amidst the COVID‐19 pandemic. However, those in conflict‐based settings with fragile healthcare systems meet additional challenges. This study reviews violence, conflict and mental health among HCWs in five countries: Syria, Palestine, Yemen, Afghanistan and Lebanon. Our study reports that HCWs are targeted by violence, bombings, mistreatment and different forms of abuse, including verbal and physical. With the additional burdens of the pandemic including prolonged working hours, limited resources and insufficient humanitarian aid, the healthcare workers fall victim to increased levels of burnout and mental illnesses. The situation leads to dire consequences on their personal lives and professional development, compelling them to quit their job or country all together. Although healthcare workers remain resilient in these conflict‐based settings, immediate interventions are required to prevent violence against them and cater to their rapidly declining mental health.
Ensemble learning and personalized training for the improvement of unsupervised deep learning‐based synthetic CT reconstruction
Olberg, Sven, Choi, Byong Su, Park, In‐Kyung , Liang, Xiao , Kim, Jin Sung , Deng, Jie , Yan, Yulong , Park, Justin C., Park, Inkyung, Jiang, Steve B

Mayo Clinic

Medical Physics | November 7, 2022 | Volume: 50 | Issue: 3 | Pages: 1436-1449

10.1002/mp.16087 | PMID 36336718 Get It

AbstractBackgroundThe growing adoption of magnetic resonance imaging (MRI)‐guided radiation therapy (RT) platforms and a focus on MRI‐only RT workflows have brought the technical challenge of synthetic computed tomography (sCT) reconstruction to the forefront. Unpaired‐data deep learning‐based approaches to the problem offer the attractive characteristic of not requiring paired training data, but the gap between paired‐ and unpaired‐data results can be limiting.PurposeWe present two distinct approaches aimed at improving unpaired‐data sCT reconstruction results: a cascade ensemble that combines multiple models and a personalized training strategy originally designed for the paired‐data setting.MethodsComparisons are made between the following models: (1) the paired‐data fully convolutional DenseNet (FCDN), (2) the FCDN with the Intentional Deep Overfit Learning (IDOL) personalized training strategy, (3) the unpaired‐data CycleGAN, (4) the CycleGAN with the IDOL training strategy, and (5) the CycleGAN as an intermediate model in a cascade ensemble approach. Evaluation of the various models over 25 total patients is carried out using a five‐fold cross‐validation scheme, with the patient‐specific IDOL models being trained for the five patients of fold 3, chosen at random.ResultsIn both the paired‐ and unpaired‐data settings, adopting the IDOL training strategy led to improvements in the mean absolute error (MAE) between true CT images and sCT outputs within the body contour (mean improvement, paired‐ and unpaired‐data approaches, respectively: 38%, 9%) and in regions of bone (52%, 5%), the peak signal‐to‐noise ratio (PSNR; 15%, 7%), and the structural similarity index (SSIM; 6%, <1%). The ensemble approach offered additional benefits over the IDOL approach in all three metrics (mean improvement over unpaired‐data approach in fold 3; MAE: 20%; bone MAE: 16%; PSNR: 10%; SSIM: 2%), and differences in body MAE between the ensemble approach and the paired‐data approach are statistically insignificant.ConclusionsWe have demonstrated that both a cascade ensemble approach and a personalized training strategy designed initially for the paired‐data setting offer significant improvements in image quality metrics for the unpaired‐data sCT reconstruction task. Closing the gap between paired‐ and unpaired‐data approaches is a step toward fully enabling these powerful and attractive unpaired‐data frameworks.
Platelet Rich Plasma and Platelet-Related Products in the Treatment of Radiculopathy—A Systematic Review of the Literature
Kubrova, Eva , Alvarez, Gabriel A Martinez , Her, Yeng F , Pagan‐Rosado, Robert , Qu, Wenchun , D’Souza, Ryan S. , Martinez Alvarez, Gabriel A , D'Souza, Ryan S

Mayo Clinic

Biomedicines | November 7, 2022 | Volume: 10 | Issue: 11 | Pages: 2813

10.3390/biomedicines10112813 | PMID 36359333 Get It

Back pain with radicular symptoms is associated with detrimental physical and emotional functioning and economic burden. Conservative treatments including physical, pharmacologic and injection therapy may not provide clinically significant or long-standing relief. Regenerative medicine research including Platelet rich plasma (PRP), Platelet lysate (PL) or Plasma rich in growth factors (PRGF) continues to develop, however evidence appraisal for treatment of radicular pain remains lacking. Thus, we performed a systematic review to evaluate the effectiveness of epidural steroid injections containing PRP or related products to treat radicular pain. Embase, PubMed/MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), and Google Scholar databases were queried. Twelve studies were included in qualitative analysis, consisting of three randomized controlled trials and nine observational studies. The primary outcome was pain intensity, and secondary outcomes included functional improvement, anatomical changes on advanced imaging, and adverse events. All studies identified improved pain intensity and functional outcomes after epidural injection of PRP, PRGF and/or PL. Similar or longer lasting pain relief was noted in the PRP cohort compared to the cohort receiving epidural steroid injections with effects lasting up to 12–24 months. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) analysis revealed a very-low certainty of evidence due to risk of bias, indirectness, and imprecision.
Pulmonary vascular reserve with exercise in heart failure
Omote, Kazunori , Borlaug, Barry A. , Borlaug, Barry A

Mayo Clinic

European Heart Journal | November 7, 2022 | Volume: 43 | Issue: 42 | Pages: 4516-4517

10.1093/eurheartj/ehac540 | PMID 36335982 Get It

Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study
Cremer, Paul , Geske, Jeffrey B. , Owens, Anjali , Jaber, Wael A. , Saberi, Sara , Wang, Andrew , Naidu, Srihari S. , Smedira, Nicholas G. , Wang, Qiuqing, Wolski, Kathy , Lampl, Kathy, Sehnert, Amy J. , Nissen, Steven E. , Desai, Milind Y. , Cremer, Paul C , Saberi, Sara , Wang, Andrew , Sherrid, Mark , Naidu, Srihari S , Smedira, Nicholas G , Sehnert, Amy J , Nissen, Steven E , Desai, Milind Y , Geske, Jeffrey B , Harb, Serge C. , Sherrid, Mark V. , Schaff, Hartzell V.

Mayo Clinic

Circulation: Cardiovascular Imaging | November 6, 2022 | Volume: 15 | Issue: 12 | Pages: No page available

10.1161/circimaging.122.014986 | PMID 36335645 Get It

Background: In the randomized phase 3 VALOR-HCM study (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy) of patients with obstructive hypertrophic cardiomyopathy, mavacamten reduced the need for septal reduction therapy. Because mavacamten improves ventricular compliance, this sub-study examined the effects of treatment with this cardiac myosin inhibitor on diastolic function. Methods: Symptomatic obstructive hypertrophic cardiomyopathy patients on maximally tolerated medical therapy referred for septal reduction therapy were randomized 1:1 to mavacamten or placebo. At baseline and week 16, a resting and stress echocardiogram was performed with interpretation by a core laboratory. In this exploratory substudy, the principal end point was the change in parameters used to define the grade of diastolic function in patients treated with mavacamten and placebo. A related objective was to assess the proportion of patients with an improvement in diastolic function grade. A secondary aim was to assess for correlation between diastolic function parameters and the secondary end points from VALOR-HCM: New York Heart Association class, quality of life, and cardiac biomarkers. Results: Diastolic dysfunction grade was evaluable in 98 patients at baseline and week 16. Among patients treated with mavacamten, 29.4% (15 of 51) demonstrated improvement in diastolic function grade compared with 12.8% (6 of 47) patients with placebo ( P =0.05). Average E/e’ ratio decreased significantly in patients treated with mavacamten (−3.4±5.3) compared with placebo (0.57±3.5; P <0.001). Indexed left atrial volumes (mL/m 2 ) also decreased significantly in patients who received mavacamten (−5.2±7.8) compared with placebo (−0.51±8.1; P =0.005). After adjustment for change in left ventricular outflow tract gradient and mitral regurgitation, mavacamten was significantly associated with a decrease in average E/e’ ratio and indexed left atrial volumes. Change in average E/e’ ratio was significantly correlated with the secondary end points from VALOR-HCM. Conclusions: In this exploratory substudy, after 16 weeks of therapy, mavacamten improved diastolic function, and this change correlated with improvement in clinical and biomarker end points. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04349072.
Outcomes of catheter ablation for ventricular tachycardia in patients with sarcoidosis: Insights from the National Inpatient Sample database (2002–2018)
Tan, Jian Liang , Jin, Chengyue , Lee, Justin Z. , Gaughan, John P. , Iwai, Sei , Russo, Andrea M.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | November 6, 2022 | Volume: 33 | Issue: 12 | Pages: 2585-2598

10.1111/jce.15708 | PMID 36335632 Get It

AbstractIntroductionData on utilization, major complications, and in‐hospital mortality of catheter ablation (CA) for sarcoidosis‐related ventricular tachycardia (VT) are limited. We sought to determine the outcomes of sarcoidosis‐related VT, and incidence and predictors of complications associated with the CA procedure.MethodsWe queried the 2002–2018 National Inpatient Sample database to identify patients aged ≥18 years with sarcoidosis admitted with VT. A 1:3 propensity score‐matched (PSM) analysis was used to compare patient outcomes between CA and medically managed groups. Multivariable regression was performed to determine independent predictors of in‐hospital mortality and procedural complications associated with the CA procedure.ResultsOf 3220 sarcoidosis patients with VT, 132 (4.1%) underwent CA. Patients who underwent CA were younger, male predominant, more likely Caucasian, had differences in baseline comorbidities including more likely to have heart failure, less likely to have prior myocardial infarction, COPD, or severe renal disease, had a higher mean household income, and more likely admitted to a larger/urban teaching hospital. After PSM, we examined 106 CA cases and 318 medically managed cases. There was a trend toward a lower in‐hospital mortality rate in the CA group when compared to the medically managed group (1.9% vs. 6.6%, p = 0.08). The most common complications were pericardial drainage (5.3%), postoperative hemorrhage (3.8%), accidental puncture periprocedure (3.0%), and cardiac tamponade (2.3%). Independent predictors of in‐hospital mortality and procedural complications among the CA group included congestive heart failure (odds ratio [OR], 13.2; 95% confidence interval [CI], 1.7–104.2) and mild to moderate renal disease (OR, 3.9; 95% CI, 1.1–13.3).ConclusionsCompared to patients with sarcoidosis‐related VT who received medical therapy alone, those who underwent CA have a trend for a lower mortality rate despite procedure‐related complications occurring as high as 9.1%. Additional studies are recommended to better evaluate the benefits and risks of VT ablation in this group.
Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks
Desai, Milind Y. , Owens, Anjali , Geske, Jeffrey B. , Wolski, Kathy , Saberi, Sara , Wang, Andrew , Cremer, Paul , Naidu, Srihari S. , Smedira, Nicholas G. , McErlean, Ellen, Sewell, Christina , Balasubramanyam, Aarthi, Lampl, Kathy, Sehnert, Amy J. , Nissen, Steven E. , Sherrid, Mark , Cremer, Paul C , Naidu, Srihari S , Smedira, Nicholas G , Schaff, Hartzell , Sewell, Christina , Sehnert, Amy J , Nissen, Steven E , Geske, Jeffrey B , Saberi, Sara , Wang, Andrew , Sherrid, Mark V. , Schaff, Hartzell V.

Mayo Clinic

Circulation | November 6, 2022 | Volume: 147 | Issue: 11 | Pages: 850-863

10.1161/circulationaha.122.062534 | PMID 36335531 Get It

Background: Septal reduction therapy (SRT) in patients with intractable symptoms from obstructive hypertrophic cardiomyopathy (oHCM) is associated with variable morbidity and mortality. The VALOR-HCM trial (A Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy) examined the effect of mavacamten on the need for SRT through week 32 in oHCM. Methods: A double-blind randomized placebo-controlled multicenter trial at 19 US sites included patients with oHCM on maximal tolerated medical therapy referred for SRT with left ventricular outflow tract gradient ≥50 mm Hg at rest or provocation (enrollment, July 2020–October 2021). The group initially randomized to mavacamten continued the drug for 32 weeks, and the placebo group crossed over to dose-blinded mavacamten from week 16 to week 32. Dose titrations were based on investigator-blinded echocardiographic assessment of left ventricular outflow tract gradient and left ventricular ejection fraction. The principal end point was the proportion of patients proceeding with SRT or remaining guideline eligible at 32 weeks in both treatment groups. Results: From the 112 randomized patients with oHCM, 108 (mean age, 60.3 years; 50% men; 94% in New York Heart Association class III/IV) qualified for week 32 evaluation (56 in the original mavacamten group and 52 in the placebo cross-over group). After 32 weeks, 6 of 56 patients (10.7%) in the original mavacamten group and 7 of 52 patients (13.5%) in the placebo cross-over group met SRT guideline criteria or elected to undergo SRT. After 32 weeks, a sustained reduction in resting left ventricular outflow tract gradient (−33.0 mm Hg [95% CI, −41.1 to −24.9]) and Valsalva left ventricular outflow tract gradient (−43.0 mm Hg [95% CI, −52.1 to −33.9]) was observed in the original mavacamten group. A similar reduction in resting (−33.7 mm Hg [95% CI, −42.2 to −25.2]) and Valsalva (−52.9 mm Hg [95% CI, −63.2 to −42.6]) gradients was quantified in the cross-over group after 16 weeks of mavacamten. After 32 weeks, improvement by ≥1 New York Heart Association class was observed in 48 of 53 patients (90.6%) in the original mavacamten group and 35 of 50 patients (70%) after 16 weeks in the cross-over group. Conclusions: In severely symptomatic patients with oHCM, 32 weeks of mavacamten treatment showed sustained reduction in the proportion proceeding to SRT or remaining guideline eligible, with similar effects observed in patients who crossed over from placebo after 16 weeks. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04349072.
Predictors of Gastrointestinal Bleeding in Patients Following Left Ventricular Assist Device Implantation: A Systematic Review and meta-analysis
Gangwani, Manesh Kumar , Aziz, Muhammad , Nawras, Ali, Priyanka, Fnu , Ahmed, Zohaib , Khan, Raja Samir , Qamar, Mohammad Aadil , Haroon, Fawad, Aziz, Abeer , Lee‐Smith, Wade , Ravi, Shri Jai Kirshan , Parikh, Vishal , Alyousif, Zakaria, Mahmood, Asif , Tariq, Raseen , Rai, Devesh , Aronow, Wilbert S. , Tariq, Raseen , Nawras, Ali T. , Mahmood, Asif

Mayo Clinic

Future Cardiology | November 5, 2022 | Volume: 18 | Issue: 12 | Pages: 957-967

10.2217/fca-2022-0054 | PMID 36334072 Get It

Evolution of a globally unique SARS-CoV-2 Spike E484T monoclonal antibody escape mutation in a persistently infected, immunocompromised individual
Halfmann, Peter , Minor, Nicholas R. , Haddock, Luis A. , Maddox, Robert James, Riemersa, Kasen K., Prasad, A. Mallikarjuna, Alman, Kirsten J., Florek, Kelsey R. , Bateman, Allen , Safdar, Nasia , Andes, David R. , Kawaoka, Yoshihiro , Yao, Joseph D. , O’Connor, David H. , Halfmann, Peter J , Haddock Iii, Luis A , Florek, Kelsey , O'Connor, David H , Maddox, Robert, Moreno, Gage K. , Braun, Katarina M. , Baker, David , Prasad, Ankur, Lambert, Matthew C, Westergaard, Ryan P. , Fida, Madiha , Friedrich, Thomas C.

Mayo Clinic

Virus Evolution | November 5, 2022 | Volume: 9 | Issue: 2 | Pages: No page available

10.1093/ve/veac104 | PMID 37692895 Get It

Abstract Prolonged infections in immunocompromised individuals may be a source for novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants, particularly when both the immune system and antiviral therapy fail to clear the infection and enable within-host evolution. Here we describe a 486-day case of SARS-CoV-2 infection in an immunocompromised individual. Following monotherapy with the monoclonal antibody Bamlanivimab, the individual’s virus acquired resistance, likely via the earliest known occurrence of Spike amino acid variant E484T. Recently, E484T has arisen again as a derivative of E484A in the Omicron Variant of Concern, supporting the hypothesis that prolonged infections can give rise to novel variants long before they become prevalent in the human population.
Characterization of myocardial mechanics and its prognostic significance in patients with severe aortic stenosis undergoing aortic valve replacement
Bi, Xiaojun , Yeung, Darwin F. , Thaden, Jeremy J. , Nhola, Lara F., Pochettino, Alberto , Greason, Kevin L. , Villarraga, Hector R. , Greason, Kevin , Bi, Xiaojun, Schaff, Hartzell V. , Pislaru, Sorin V. , Pellikka, Patricia A. , Nkomo, Vuyisile T.

Mayo Clinic

European Heart Journal Open | November 5, 2022 | Volume: 2 | Issue: 6 | Pages: No page available

10.1093/ehjopen/oeac074 | PMID 36540107 Get It

Abstract Aims Aortic stenosis (AS) induces characteristic changes in left ventricular (LV) mechanics that can be reversed after aortic valve replacement (AVR). We aimed to comprehensively characterize LV mechanics before and after AVR in patients with severe AS and identify predictors of short-term functional recovery and long-term survival. Methods and results We prospectively performed comprehensive strain analysis by 2D speckle-tracking echocardiography in 88 patients with severe AS and LV ejection fraction ≥50% (mean age 71 ± 12 years, 42% female) prior to and within 7 days after AVR. Patients were followed for up to 5.2 years until death from any cause or last encounter. Within days after AVR, we observed an absolute increase in global longitudinal strain (GLS) (−16.0 ± 2.0% vs. −18.5 ± 2.1%, P&lt;0.0001) and a decrease in apical rotation (10.5 ± 4.0° vs. 8.3 ± 2.8°, P = 0.0002) and peak systolic twist (18.2 ± 5.0° vs. 15.5 ± 3.8°, P = 0.0008). A baseline GLS is less negative than −16.2% was 90% sensitive and 67% specific in predicting a ≥ 20% relative increase in GLS. During a median follow-up of 3.8 years, a global circumferential systolic strain rate (GCSRs) less negative than −1.9% independently predicted lower survival. Conclusion In patients with severe AS, a reversal in GLS, apical rotation, and peak systolic twist abnormalities towards normal occurs within days of AVR. Baseline GLS is the strongest predictor of GLS recovery but neither was associated with long-term survival. In contrast, abnormal baseline GCSRs are associated with worse outcomes.